Larimar Therapeutics, Inc. (LRMR)
2.695
-0.04
(-1.28%)
USD |
NASDAQ |
Nov 12, 16:00
2.695
0.00 (0.00%)
After-Hours: 17:34
Larimar Therapeutics Price to Book Value : 2.208 for Nov. 12, 2026
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| November 11, 2026 | 2.237 |
| November 10, 2026 | 2.204 |
| November 09, 2026 | 2.073 |
| November 06, 2026 | 1.958 |
| November 05, 2026 | 1.901 |
| November 04, 2026 | 2.262 |
| November 03, 2026 | 2.081 |
| November 02, 2026 | 1.942 |
| October 30, 2026 | 2.024 |
| October 29, 2026 | 2.188 |
| October 28, 2026 | 2.081 |
| October 27, 2026 | 1.958 |
| October 26, 2026 | 1.836 |
| October 23, 2026 | 1.926 |
| October 22, 2026 | 1.860 |
| October 21, 2026 | 1.983 |
| October 20, 2026 | 2.000 |
| October 19, 2026 | 1.737 |
| October 16, 2026 | 1.627 |
| October 15, 2026 | 1.631 |
| October 14, 2026 | 1.713 |
| October 13, 2026 | 1.77 |
| October 12, 2026 | 2.073 |
| October 09, 2026 | 2.188 |
| October 08, 2026 | 2.212 |
| Date | Value |
|---|---|
| October 07, 2026 | 2.254 |
| October 06, 2026 | 2.278 |
| October 05, 2026 | 2.344 |
| October 02, 2026 | 2.426 |
| October 01, 2026 | 2.508 |
| September 30, 2026 | 2.618 |
| September 29, 2026 | 2.573 |
| September 28, 2026 | 2.598 |
| September 25, 2026 | 2.520 |
| September 24, 2026 | 2.721 |
| September 23, 2026 | 3.167 |
| September 22, 2026 | 3.130 |
| September 21, 2026 | 3.138 |
| September 18, 2026 | 3.106 |
| September 17, 2026 | 3.114 |
| September 16, 2026 | 3.220 |
| September 15, 2026 | 3.204 |
| September 14, 2026 | 3.098 |
| September 11, 2026 | 3.212 |
| September 10, 2026 | 3.155 |
| September 09, 2026 | 3.171 |
| September 08, 2026 | 3.339 |
| September 04, 2026 | 3.138 |
| September 03, 2026 | 3.138 |
| September 02, 2026 | 3.171 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.257 |
| Alnylam Pharmaceuticals, Inc. | 5.817 |
| Anika Therapeutics, Inc. | 1.347 |
| Savara, Inc. | 8.976 |
| Vericel Corp. | 7.627 |
Price to Book Value Related Metrics
| PEG Ratio | -0.0503 |
| Price | 2.695 |
| Earnings Yield | -73.58% |
| Market Cap | 281.31M |
| PEGY Ratio | -0.0503 |